肾细胞癌复发、癌特异性死亡和全因死亡预后模型的验证
复发模型C统计量0.62–0.83,癌特异性死亡模型0.60–0.89,全因死亡模型0.60–0.73;在透明细胞肾细胞癌中,Mayo Clinic模型在辅助治疗决策曲线上表现最佳。
要点
- 肾癌复发预后模型C统计量范围为0.62–0.83,因模型分层方式而异。
- 癌特异性死亡模型C统计量0.60–0.89,全因死亡模型0.60–0.73。
- 透明细胞肾细胞癌中Mayo Clinic模型用于辅助治疗选择时净获益最佳。
核心结论
- 模型性能差异较大,部分模型适合临床使用;若用预测模型选择辅助治疗,Mayo Clinic模型在加拿大大型当代队列中表现最佳。
研究设计与样本
- 加拿大肾癌信息系统为前瞻性队列,自2011年1月1日至今纳入14家机构管理的患者。
- 验证15个肾癌复发模型、6个癌特异性死亡模型和4个全因死亡模型。
主要发现
- 肾癌复发模型C统计量范围为0.62–0.83,取决于模型是否未经进一步分层应用于全部患者、特定风险组或特定组织学亚型。
- 癌特异性死亡模型C统计量范围为0.60–0.89。
- 全因死亡模型C统计量范围为0.60–0.73。
- 在透明细胞肾细胞癌患者中,决策曲线分析显示预防复发和癌症相关死亡的最佳辅助治疗选择模型为Mayo Clinic预测模型。
关键数值与推荐
- 复发模型C统计量0.62–0.83。
- 癌特异性死亡模型C统计量0.60–0.89。
- 全因死亡模型C统计量0.60–0.73。
- 采用5年校准图评估校准,术后5年决策曲线分析评估净获益。
临床怎么用
- 术后预后工具可改善未来复发风险预测、患者咨询、辅助治疗资格评估和适当随访监测。
- 若使用预测模型选择辅助治疗,Mayo Clinic模型在加拿大大型当代队列中表现最佳。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Postoperative prognostic tools allow for improved prediction of future recurrence risk, patient counseling, assessment of eligibility for adjuvant treatments, and appropriate follow-up surveillance. The purpose of this analysis was to validate prognostic models for patients with kidney cancer. MATERIALS AND METHODS: The Canadian Kidney Cancer information system is a prospective cohort of patients managed at 14 institutions since January 1, 2011, to present. The Canadian Kidney Cancer information system was used to assess 15 predictive models for kidney cancer recurrence, 6 for cancer-specific mortality, and 4 for all-cause mortality in patients with a solitary, nonmetastatic kidney tumor treated with surgery (partial or radical nephrectomy). Discrimination was measured using C statistics, 5-year calibration plots for calibration, and decision curve analysis at 5 years after surgery for net benefit when considering adjuvant therapy. RESULTS: Seven thousand one hundred seventy-four patients were included. For kidney cancer recurrence, C statistics ranged from 0.62 to 0.83, depending on whether the model was derived and applied to all patients without further stratification, specific risk groups, or specific histologic subtypes. Cancer-specific mortality models had C statistics ranging from 0.60 to 0.89 and all-cause mortality models from 0.60 to 0.73. Using decision curve analysis in patients with clear-cell renal cell carcinoma, the best models for choosing adjuvant therapy to prevent recurrence and cancer-related death were the Mayo Clinic prediction models. CONCLUSIONS: Model performance varied considerably with some suitable for clinical use. If using prediction models to select adjuvant therapy, the Mayo Clinic models were best when applied to a large contemporary cohort of Canadian patients.
引用
- Robert A, Mallick R, McIsaac DI, et al. Validation of Prognostic Models for Renal Cell Carcinoma Recurrence, Cancer-Specific Mortality, and All-Cause Mortality. J Urol. 2024. PMID: 39622017. doi:10.1097/JU.0000000000004348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。